Invezz

OraSure Technologies (OSUR)

Nasdaq Market Closed

OraSure Technologies Inc. is a healthcare diagnostics and sample management company listed under the symbol OSUR. The company develops, manufactures and sells products designed to make medical testing and specimen collection more accessible, including solutions that can be used outside traditional laboratory settings.

OraSure is best known for diagnostic testing platforms and oral fluid collection technologies. Its product portfolio has included tests and collection devices related to infectious disease, sexual health, molecular sampling and public health applications. The company’s technologies support both direct diagnostic testing and the collection, stabilization and transport of biological samples for analysis by laboratories and healthcare organizations.

The business operates at the intersection of diagnostics, population health and healthcare data workflows. By enabling easier sample collection and broader testing access, OraSure serves customers such as healthcare providers, laboratories, government agencies, public health programs, employers and research organizations. Its products can be relevant in settings where rapid testing, at-home collection or large-scale screening programs are needed.

Revenue is primarily generated from the sale of diagnostic products and sample management solutions, with the United States representing its largest market. OraSure’s results can be influenced by testing demand, regulatory approvals, public health funding, product mix and the competitive landscape for diagnostics and laboratory services.

For investors, OSUR represents exposure to a specialized medical technology company focused on practical tools that expand access to testing and sample collection. Its long-term positioning depends on innovation, manufacturing execution, regulatory compliance and the ability to adapt its product portfolio to changing healthcare and public health priorities.

3.95 USD
3.79 USD
−0.05 (-1.25%)
After-hours

Last updated

Market Cap
275.39M
P/E
P/FCF
P/S
2.44
Enterprise Value
98.66M
Sector
Health Care
Industry
Surgical and Medical Instruments and Apparatus
Address
220 E FIRST ST, BETHLEHEM, PA, 18015
Investing.com

Is Co-Diagnostics National Security’s Next Diagnostic Pick?

May 28, 2026, 12:07 PM
GlobeNewswire Inc.

OraSure Technologies Appoints John D. Bertrand to its Board of Directors

Apr 16, 2026, 20:10 PM
GlobeNewswire Inc.

Drug Screening Market Trends 2026–2031: Chromatography and Mass Spectrometry Held a 44.77% Share in 2025 Amid Growing Demand for Advanced Testing, Reports Mordor Intelligence

Apr 03, 2026, 03:15 AM
GlobeNewswire Inc.

OTC/DTC Infectious Disease Diagnostics Research Report 2026: Market Strategies, Trends, and Forecasts 2025-2029 - Privacy, Digital Access, and Rapid Results Accelerate Adoption

Feb 03, 2026, 08:00 AM
GlobeNewswire Inc.

OraSure Technologies Confirms Receipt of Director Nominations from Altai Capital

Jan 15, 2026, 13:00 PM
GlobeNewswire Inc.

OraSure Submits CT/NG Molecular Self-Test and Colli-Pee™ Urine Collection Device for FDA Review

Jan 05, 2026, 08:00 AM
GlobeNewswire Inc.

Global At-Home Testing Market to Reach USD 11,877.8 Million by 2035 with a CAGR of 4.8%, Driven by Rising Consumer Demand for Self-Diagnostic Tools | Future Market Insights, Inc.

Jan 16, 2025, 19:30 PM
GlobeNewswire Inc.

Microbiome Diagnostics Market to hit USD 429.2 million by 2032, says Global Market Insights Inc.

Oct 29, 2024, 04:00 AM
GlobeNewswire Inc.

OraSure to Announce Second Quarter 2024 Financial Results and Host Earnings Call on August 6th - GlobeNewswire

Jul 22, 2024, 16:06 PM
GlobeNewswire Inc.

OraSure Technologies Supports National HIV Testing Day

Jun 27, 2024, 07:05 AM
Zacks Investment Research

OraSure Technologies (OSUR) Q1 Earnings Meet Estimates

May 08, 2024, 18:20 PM
GlobeNewswire Inc.

OraSure to Announce First Quarter 2024 Financial Results and Host Earnings Call on May 8th

Apr 22, 2024, 08:00 AM
Zacks Investment Research

Insulet (PODD) Surpasses Q4 Earnings and Revenue Estimates

Feb 22, 2024, 17:20 PM
Zacks Investment Research

Baxter International (BAX) Tops Q4 Earnings and Revenue Estimates

Feb 08, 2024, 08:40 AM
Zacks Investment Research

Abbott (ABT) Q4 Earnings Match Estimates

Jan 24, 2024, 08:40 AM
Zacks Investment Research

Zacks.com featured highlights Otter Tail, OraSure, BioMarin and Regeneron

Jan 19, 2024, 03:45 AM
Zacks Investment Research

Buy These 4 Low-Beta Stocks to Counter Market Volatility

Jan 18, 2024, 07:36 AM
GlobeNewswire Inc.

OraSure Technologies, Inc. Secures Strategic Distribution Rights and Invests in Sapphiros, a Next-Generation Consumer Diagnostics Company

Jan 04, 2024, 07:05 AM
Zacks Investment Research

After Golden Cross, OraSure Technologies (OSUR)'s Technical Outlook is Bright

Nov 27, 2023, 09:55 AM
GlobeNewswire Inc.

OraSure to Participate in Upcoming Investor Conferences

Nov 13, 2023, 16:15 PM
Market Cap
275.39M
Enterprise Value
98.66M
P/E
P/B
0.88
P/S
2.44
EV / EBITDA
-1.58
EV / Sales
0.87
EPS
-1.09
Dividend Yield
0%
P/FCF
P/CF
Free Cash Flow
-47.88M
ROE
-23.96%
ROA
-19.8%
Debt / Equity
0
Current Ratio
5.46
Quick Ratio
4.77
Cash
4.01
Avg Volume
724.75K
Fundamentals Snapshot Price
4

Income Statement

Line Item 2026 Q1 2025 Q4 2025 Q3 2025 Q2 2025 Q1
Revenue 27.93M 26.76M 27.09M 31.24M 29.93M
Gross profit 11.8M 10.97M 11.77M 13.16M 12.3M
Operating income -23.27M -19.84M -16.09M -18.03M -18.74M
EBITDA -21.01M -12.86M -13.71M -14.88M -15.97M
Net income -22.38M -19.29M -13.71M -19.69M -16.04M
Basic EPS -0.32 -0.27 -0.19 -0.26 -0.21
Diluted EPS -0.32 -0.27 -0.19 -0.26 -0.21

Balance Sheet

Line Item 2026 Q1 2025 Q4 2025 Q3 2025 Q2 2025 Q1
Total assets 379.17M 403.17M 423.1M 445.04M 457.61M
Total liabilities 65.85M 62.34M 61.12M 64.31M 61.33M
Total equity 313.32M 340.83M 361.98M 380.72M 396.28M
Cash & equivalents 176.96M 199.28M 216.48M 234.58M 247.57M
Current assets 240.78M 261.91M 283.01M 301.44M 313.78M
Current liabilities 44.08M 39.8M 40.25M 42.35M 25.42M

Cash Flow

Line Item 2026 Q1 2025 Q4 2025 Q3 2025 Q2 2025 Q1
Operating cash flow -13.9M -9M -10.07M -10.22M -19.73M
Investing cash flow -913K -4.42M -821K -1.94M 370K
Financing cash flow -6.28M -5.11M -5.08M -5.8M -953K
Change in cash -22.31M -17.2M -18.1M -12.99M -20.19M
Kind Filing Date Link
edgar index 4 — ORASURE TECHNOLOGIES INC View Filing
edgar index 4 — ORASURE TECHNOLOGIES INC View Filing
edgar index 4 — ORASURE TECHNOLOGIES INC View Filing
edgar index 3 — ORASURE TECHNOLOGIES INC View Filing
edgar index 4 — ORASURE TECHNOLOGIES INC View Filing
edgar index 4 — ORASURE TECHNOLOGIES INC View Filing
form 4 Form 4 — Boyd Steven Kyle View Filing
form 4 Form 4 — Gagliano Nancy J View Filing
form 4 Form 4 — McMahon Robert W. View Filing
form 4 Form 4 — Marmora Lelio View Filing
form 4 Form 4 — Boyd Steven Kyle View Filing
form 4 Form 4 — Bertrand John D. View Filing
form 4 Form 4 — Boyd Steven Kyle View Filing
edgar index 10-Q — ORASURE TECHNOLOGIES INC View Filing
edgar index 8-K — ORASURE TECHNOLOGIES INC View Filing
eight k text 8-K — 8-K View Filing
edgar index SCHEDULE 13D/A — ORASURE TECHNOLOGIES INC View Filing
edgar index PRE 14A — ORASURE TECHNOLOGIES INC View Filing
edgar index 8-K — ORASURE TECHNOLOGIES INC View Filing
edgar index DEFA14A — ORASURE TECHNOLOGIES INC View Filing
edgar index DEFA14A — ORASURE TECHNOLOGIES INC View Filing
eight k text 8-K — 8-K View Filing
edgar index SCHEDULE 13G — ORASURE TECHNOLOGIES INC View Filing
edgar index 4 — ORASURE TECHNOLOGIES INC View Filing
edgar index 8-K — ORASURE TECHNOLOGIES INC View Filing
edgar index DEFA14A — ORASURE TECHNOLOGIES INC View Filing
eight k text 8-K — 8-K View Filing
edgar index SCHEDULE 13G/A — ORASURE TECHNOLOGIES INC View Filing
form 4 Form 4 — Boyd Steven Kyle View Filing
form 4 Form 4 — Boyd Steven Kyle View Filing
edgar index 4 — ORASURE TECHNOLOGIES INC View Filing
edgar index 4 — ORASURE TECHNOLOGIES INC View Filing
form 4 Form 4 — EGLINTON MANNER CARRIE View Filing
form 4 Form 4 — McGrath Kenneth J View Filing
edgar index 4 — ORASURE TECHNOLOGIES INC View Filing
edgar index DFAN14A — ORASURE TECHNOLOGIES INC View Filing
edgar index SCHEDULE 13D/A — ORASURE TECHNOLOGIES INC View Filing
edgar index DEFA14A — ORASURE TECHNOLOGIES INC View Filing
edgar index 4 — ORASURE TECHNOLOGIES INC View Filing
edgar index 4 — ORASURE TECHNOLOGIES INC View Filing
form 4 Form 4 — EGLINTON MANNER CARRIE View Filing
form 4 Form 4 — McGrath Kenneth J View Filing
edgar index 10-K — ORASURE TECHNOLOGIES INC View Filing
ten k section 10-K — business View Filing
ten k section 10-K — mda View Filing
ten k section 10-K — risk_factors View Filing
edgar index 8-K — ORASURE TECHNOLOGIES INC View Filing
eight k text 8-K — 8-K View Filing
edgar index 4 — ORASURE TECHNOLOGIES INC View Filing
edgar index 4 — ORASURE TECHNOLOGIES INC View Filing
form 4 Form 4 — EGLINTON MANNER CARRIE View Filing
form 4 Form 4 — McGrath Kenneth J View Filing
form 4 Form 4 — Anthony Michele Marie View Filing
form 4 Form 4 — EGLINTON MANNER CARRIE View Filing
form 4 Form 4 — EGLINTON MANNER CARRIE View Filing
form 4 Form 4 — EGLINTON MANNER CARRIE View Filing
form 4 Form 4 — McGrath Kenneth J View Filing
form 4 Form 4 — McGrath Kenneth J View Filing
form 4 Form 4 — McGrath Kenneth J View Filing
form 4 Form 4 — Anthony Michele Marie View Filing
form 4 Form 4 — Anthony Michele Marie View Filing
form 4 Form 4 — Anthony Michele Marie View Filing
edgar index 8-K — ORASURE TECHNOLOGIES INC View Filing
eight k text 8-K — 8-K View Filing
edgar index SCHEDULE 13G/A — ORASURE TECHNOLOGIES INC View Filing
edgar index SCHEDULE 13D/A — ORASURE TECHNOLOGIES INC View Filing
edgar index DFAN14A — ORASURE TECHNOLOGIES INC View Filing
edgar index DEFA14A — ORASURE TECHNOLOGIES INC View Filing
edgar index 8-K — ORASURE TECHNOLOGIES INC View Filing
eight k text 8-K — 8-K View Filing
edgar index 4 — ORASURE TECHNOLOGIES INC View Filing
edgar index SCHEDULE 13D/A — ORASURE TECHNOLOGIES INC View Filing
edgar index DEFA14A — ORASURE TECHNOLOGIES INC View Filing
form 4 Form 4 — Kenny John P. View Filing
edgar index 144 — ORASURE TECHNOLOGIES INC View Filing